GeneDx CEO on Accelerating Rare Disease Diagnosis with Genomic Testing

GeneDx's Financial Performance and Growth

• 📈 GeneDx achieved over $100 million in revenue in its most recent quarter, surpassing previous financial milestones.
• 🚀 The company raised its fiscal year guidance and flipped to a profit from a prior loss, signaling strong financial health.
• ⚡ Sales for exome and genome testing saw significant growth, increasing by 69%.

Addressing the Diagnostic Odyssey

• 🎯 GeneDx focuses on diagnosing children with rare diseases, aiming to shorten the average 5-year diagnostic odyssey.
• 💡 The company is working to raise awareness among clinicians about the accessibility and benefits of advanced genetic testing.
• ⏱️ GeneDx can now deliver diagnostic answers within weeks, if not hours, a significant improvement over historical timelines.

Overcoming Barriers to Testing

• 💰 Historically, rare disease tests were both time-consuming and expensive, but GeneDx has reduced costs and turnaround times.
• ⏱️ A whole genome sequencing can now be completed in as little as 48 hours.
• 🏥 Insurance companies increasingly cover these tests, partly due to the health economic benefits and potential savings to the healthcare system.
• 💰 The cost per test, with insurance coverage, averages around $3,700.

Advancements in Gene Discovery and Data Analysis

• 🔬 GeneDx is making new gene disease discoveries almost weekly, contributing to the understanding of over 7,000 known rare diseases.
• 🧬 With a database of 850,000 exome and genome tests, the company has enriched data for rare disease diagnosis.
• 👨‍👩‍👧‍👦 Testing often includes parents (60% of the time) to analyze denovo mutations and genotypic data.
• 📊 The company combines genotypic data with 7 million phenotypic data points (like clinical notes and symptoms) to accurately interpret genetic variants.

The Impact of Early Diagnosis and Patient Advocacy

• 🌍 While individual rare diseases are uncommon, collectively, they affect 25-30 million people in the US.
• 🌱 The CEO shares a personal connection, highlighting how patient advocacy and research funding, exemplified by the Cystic Fibrosis Foundation, drive significant discoveries and improve patient outcomes.
• 🧠 GeneDx primarily focuses on the pediatric neurology space, testing for conditions like epilepsy, autism, and developmental delays.
• 🩺 Updated guidance from the American Academy of Pediatrics now recommends that pediatricians order exome and genome testing for children with developmental delays.